Core Laboratories N.V.
NYSE:CLBOil & Gas Equipment & Services
+$0.12 today
- Market cap
- $387.21M
- Beta
- 0.99
- P/E (TTM)
- 18.3
- EPS (TTM)
- $0.63
- Dividend yield
- 0.35%
Volume 0.52M
Average 0.49M
CLB Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Core Laboratories N.V.NYSE: CLB
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns positive
Q1 FY2026 accounts receivables was $5.01M, compared with -$5.94M a year earlier. Trailing-twelve-month accounts receivables was $5.72M. Over 3 fiscal years it compounded at -21.1% a year.
Context
- Accounts receivables amounted to 0.9% of revenue in FY2025, up 0.3 pp from a year earlier.
- Accounts receivables grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts receivables holds near $5.01M or moves back toward the trailing-twelve-month quarterly average of $1.43M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (4.95M) USD
- Year-over-year change
- -37.1%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (4.95M) | -37.1% |
| FY2024 | 2024-12-31 | (3.61M) | -38.0% |
| FY2023 | 2023-12-31 | (2.62M) | +74.0% |
| FY2022 | 2022-12-31 | (10.08M) | +25.5% |
| FY2021 | 2021-12-31 | (13.52M) | — |
Accounts Receivables vs competitors
How CLB compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +275.6% is the 2nd highest of 8, against a peer median of -44.4%.
- Accounts receivables amounts to 1.1% of revenue for CLB, versus a peer median of 2.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $88.04M USD | +1878.5% | — | 2.7% | |
| LTM Mar 2026 | $20.15M USD | -165.7% | — | 2.6% | |
| LTM Mar 2026 | $20.12M USD | +126.1% | -17.5% | 5.7% | |
| LTM Mar 2026 | $15.29M USD | +246.3% | — | 5.6% | |
| LTM Mar 2026 | $9.46M USD | -44.4% | -43.7% | 2.1% | |
| LTM Mar 2026 | $5.72M USD | +275.6% | -21.1% | 1.1% | |
| LTM Mar 2026 | $5M USD | -94.3% | — | 0.5% | |
| LTM Mar 2026 | $2.73M USD | -142.1% | +31.5% | 0.1% | |
| LTM Mar 2026 | $1.54M USD | — | — | 121.3% | |
| LTM Mar 2026 | CA$0 CAD | — | — | 0.0% | |
| Peer median (excluding CLB) | — | -44.4% | -17.5% | 2.6% | |
Competitors are the stored peer set for CLB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 20.22M | 19.66M | 37.03M | 32.15M | 31.8M |
| Depreciation & Amortization | 18.52M | 17.16M | 15.78M | 14.95M | 14.65M |
| Deferred Income Tax | 6.01M | 433K | (10.81M) | 674K | (4.74M) |
| Stock-Based Compensation | 19.09M | 7.76M | 13.97M | 3.76M | 7.14M |
| Change in Working Capital | (24.25M) | (25.02M) | (28.77M) | 7.88M | (5.57M) |
| Accounts Receivables | (13.52M) | (10.08M) | (2.62M) | (3.61M) | (4.95M) |
| Inventory | (4.55M) | (14.86M) | (12.98M) | 9.37M | 2.64M |
| Accounts Payables | 6.57M | 15.37M | (12.88M) | 519K | 477K |
| Other Working Capital | (12.75M) | (15.46M) | (300K) | 1.61M | (3.73M) |
| Other Non-Cash Items | (3.01M) | 4.97M | (2.41M) | (3.03M) | (6.11M) |
| Operating Cash Flow | 36.58M | 24.96M | 24.79M | 56.39M | 37.18M |
| Capital Expenditures | (13.54M) | (10.22M) | (10.58M) | (13.03M) | (14.59M) |
| Acquisitions (Net) | 873K | 240K | 0 | 0 | (1.24M) |
| Purchases of Investments | 13.54M | 0 | 0 | 0 | 0 |
| Sales of Investments | 726K | 0 | 0 | 0 | 0 |
| Other Investing Activities | (11.82M) | 6.12M | 3.93M | 6.63M | 13.6M |
| Investing Cash Flow | (10.22M) | (3.86M) | (6.65M) | (6.39M) | (2.23M) |
| Debt Repayment | (71M) | (15M) | (9M) | (38M) | (16.71M) |
| Common Stock Issued | 60M | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (8.26M) | (3.9M) | (2.2M) | (5.31M) | (12.43M) |
| Dividends Paid | (1.83M) | (1.85M) | (1.87M) | (1.88M) | (1.87M) |
| Other Financing Activities | (1.37M) | (2.62M) | (5.38M) | (775K) | (254K) |
| Financing Cash Flow | (22.46M) | (23.38M) | (18.45M) | (45.96M) | (31.26M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 3.9M | (2.28M) | (308K) | 4.04M | 3.69M |
| Free Cash Flow | 23.04M | 14.74M | 14.21M | 43.36M | 22.59M |
Core Laboratories N.V.
NYSE:CLB
Intrinsic Alpha fair value
Locked
Current Price
$8.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.